Talactoferrin fails to improve progression-free or overall survival in randomized trial vs. placebo
Article
I was disappointed to learn today that the FORTIS-M trial, a study of 720 patients with previously treated advanced NSCLC randomized to receive talactoferrin-alpha (TLF) or placebo, was reported as being negative in a press release late yesterday.